A QT/QTc and Multi-Dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration- Resistant Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2015
At a glance
- Drugs Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 07 Jun 2017 Biomarkers information updated
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.